We interview Derek O'Hagan, Senior Advisor at GlaxoSmithKline Vaccines to learn more about the future of the vaccine.

The poliovirus is on the rise for the first time in nearly 40 years.

Katrina Adlerz, Scientist at The University of Texas MD Anderson Cancer Center presents on developing meaningful biologic assays at the Cell Therapy Analytics Symposium 2022.

Discover key event highlights from Oxford Global's upcoming Vaccines Congress 2022.

Nazneen Dewji, President and CEO of Cenna Biosciences leads a discussion on the strategies to overcome the challenges ‘Oral Delivery of Peptides’.

CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.

Hot off the press, we look at this week’s breaking news stories from the Biologics industry.

June's Discussion Group welcomed a panel of industry experts to debate manufacturing and standardisation challenges for the commercialisation of cell and gene therapies.

Clinical studies testing treatments for severe COVID-19 face major delays due to eligibility issues.

In this Commentary article, we explore how reductions in testing complexity can improve access to hematopoietic stem cell therapies for patients with blood disorders. The provision of safe, effective therapies will help to ameliorate the worst impacts of these disorders for patients and afford them a better quality of life.

Key opinion leaders from Roche and Purespring Therapeutics debate future strategies for advancing cell and gene therapeutics.

Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.